Evidence-Based Complementary and Alternative Medicine

Research Article

Metabolomics Profiling to Investigate the Pharmacologic Mechanisms of Berberine for the Treatment of High-Fat Diet-Induced Nonalcoholic Steatohepatitis

Table 2

Altered metabolites in serum samples of the nonalcoholic steatohepatitis model (M) and berberine (Ber) treatment group (PC: phosphatidylcholine; LysoPC: lysophosphatidylcholine; SM: sphingomyelin; 13-HpODE: 13-hydroperoxy-octadecadienoic acid).


tR		VIP	ESI model	Formula	Metabolites	Fold changes		Classify
tR		VIP	ESI model	Formula	Metabolites	M/NC	Ber/M	Classify

8.45	468.31/512.29	2.17/1.34	[M+H]⁺/[M+FA-H]⁻	C₂₂H₄₆NO₇P	LysoPC (14:0)	↑	↓	Glycerophospholipids
8.46	311.22	1.09	[M-H]⁻	C₁₈H₃₂O₄	13-HpODE	↑	↓	Linoleic acids
8.73	508.34	1.22	[M+H]⁺	C₂₅H₅₀NO₇P	LysoPC (17:1)	↑	↓	Glycerophospholipids
8.88	522.36	4.93	[M+H]⁺	C₂₆H₅₂NO₇P	LysoPC (18:1)	↑	↓	Glycerophospholipids
8.96	548.37	1.84	[M+H]⁺	C₂₈H₅₄NO₇P	LysoPC (20:2)	↑	↓	Glycerophospholipids
9.25	305.25	4.05	[M-H]⁻	C₂₀H₃₄O₂	Eicosatrienoic acid	↑	↓	Fatty acids
9.50	295.26	1.19	[M-H]⁻	C₁₉H₃₆O₂	Phytomonic acid	↑	↓	Fatty acids
9.56	333.28	1.06	[M-H]⁻	C₂₂H₃₈O₂	Docosatrienoic acid	↑	↓	Fatty acids
9.68	309.28	2.28	[M-H]⁻	C₂₀H₃₈O₂	Eicosenoic Acid	↑	↓	Fatty acids
10.03	745.55/701.55	1.48/1.93	[M+FA-H]⁻/[M+H]⁺	C₃₉H₇₇N₂O₆P	SM (34:2)	↓	↑	Sphingolipids
10.30	830.57/874.56	1.17/1.04	[M+H]⁺/[M+FA-H]⁻	C₄₈H₈₀NO₈P	PC (40:8)	↓	↑	Glycerophospholipids
10.37	747.57	3.08	[M+FA-H]⁻	C₃₉H₇₉N₂O₆P	SM (34:1)	↓	↑	Sphingolipids
10.38	703.58	4.74	[M+H]⁺	C₃₉H₇₉N₂O₆P	SM (34:1)	↓	↑	Sphingolipids
10.52	806.57	5.08	[M+H]⁺	C₄₆H₈₀NO₈P	PC (38:6)	↓	↑	Glycerophospholipids
10.53	850.56	2.55	[M+FA-H]⁻	C₄₆H₈₀NO₈P	PC (38:6)	↓	↑	Glycerophospholipids
10.92	796.58	1.87	[M+H]⁺	C₄₅H₈₂NO₈P	PC (37:4)	↓	↑	Glycerophospholipids
10.94	731.61	1.56	[M+H]⁺	C₄₁H₈₃N₂O₆P	SM (36:1)	↓	↑	Sphingolipids
11.15	834.60/878.59	4.45/2.03	[M+H]⁺/[M+FA-H]⁻	C₄₈H₈₄NO₈P	PC (40:6)	↓	↑	Glycerophospholipids
11.40	836.62	2.27	[M+H]⁺	C₄₈H₈₆NO₈P	PC (40:5)	↓	↑	Glycerophospholipids
11.60	812.62	6.25	[M+H]⁺	C₄₆H₈₆NO₈P	PC (38:3)	↑	↓	Glycerophospholipids
12.05	811.67/855.66	3.81/2.24	[M+H]⁺/[M+FA-H]⁻	C₄₇H₉₁N₂O₆P	SM (42:3)	↓	↑	Sphingolipids

Note. The data were calculated using the integrated peak areas. The value represents fold change. VIP was obtained from OPLS-DA with a threshold of 1.0. The up and down arrows indicate a respective increased or decreased concentration of each metabolite in the HFD group versus normal control (M/NC) and berberine-treated versus HFD group (Ber/M).